KR101713027B1 - Composition for preventing or treating cancer comprising phenyloxazol derivatives - Google Patents
Composition for preventing or treating cancer comprising phenyloxazol derivatives Download PDFInfo
- Publication number
- KR101713027B1 KR101713027B1 KR1020150184931A KR20150184931A KR101713027B1 KR 101713027 B1 KR101713027 B1 KR 101713027B1 KR 1020150184931 A KR1020150184931 A KR 1020150184931A KR 20150184931 A KR20150184931 A KR 20150184931A KR 101713027 B1 KR101713027 B1 KR 101713027B1
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- oxazol
- amine
- phenyloxazole
- bromophenyl
- Prior art date
Links
- RQCBPOPQTLHDFC-UHFFFAOYSA-N 2-phenyl-1,3-oxazole Chemical class C1=COC(C=2C=CC=CC=2)=N1 RQCBPOPQTLHDFC-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 31
- 201000011510 cancer Diseases 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 230000036541 health Effects 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 12
- 235000013376 functional food Nutrition 0.000 claims abstract description 12
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 10
- 238000011319 anticancer therapy Methods 0.000 claims abstract description 4
- ACTKAGSPIFDCMF-UHFFFAOYSA-N 1,3-oxazol-2-amine Chemical compound NC1=NC=CO1 ACTKAGSPIFDCMF-UHFFFAOYSA-N 0.000 claims description 30
- -1 2,5-dimethoxyphenyl Chemical group 0.000 claims description 27
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 27
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims description 26
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 21
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 16
- 201000005202 lung cancer Diseases 0.000 claims description 16
- 208000020816 lung neoplasm Diseases 0.000 claims description 16
- 206010005003 Bladder cancer Diseases 0.000 claims description 12
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 12
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 7
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 7
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 7
- 229960002949 fluorouracil Drugs 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000005787 hematologic cancer Diseases 0.000 claims description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 206010046766 uterine cancer Diseases 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 5
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960000640 dactinomycin Drugs 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 18
- 230000006907 apoptotic process Effects 0.000 abstract description 16
- 230000026731 phosphorylation Effects 0.000 abstract description 10
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 10
- 102000001712 STAT5 Transcription Factor Human genes 0.000 abstract description 8
- 108010029477 STAT5 Transcription Factor Proteins 0.000 abstract description 8
- 230000004663 cell proliferation Effects 0.000 abstract description 6
- 230000001965 increasing effect Effects 0.000 abstract description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 4
- 239000000758 substrate Substances 0.000 abstract description 4
- 206010000830 Acute leukaemia Diseases 0.000 abstract description 3
- 230000030833 cell death Effects 0.000 abstract description 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 41
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 230000002401 inhibitory effect Effects 0.000 description 17
- 108091000080 Phosphotransferase Proteins 0.000 description 16
- 102000020233 phosphotransferase Human genes 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 9
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 9
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 8
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 108091008606 PDGF receptors Proteins 0.000 description 7
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 7
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 7
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 6
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- PHXOELCQHHPYCR-UHFFFAOYSA-N BrC1=CC=C(C=C1)C1=CN=C(O1)NC1=CC=CC2=CC=CC=C12 Chemical compound BrC1=CC=C(C=C1)C1=CN=C(O1)NC1=CC=CC2=CC=CC=C12 PHXOELCQHHPYCR-UHFFFAOYSA-N 0.000 description 5
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 5
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000003952 Caspase 3 Human genes 0.000 description 4
- 108090000397 Caspase 3 Proteins 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 108010068192 Cyclin A Proteins 0.000 description 4
- 102100025191 Cyclin-A2 Human genes 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 description 4
- 101710151814 NUAK family SNF1-like kinase 1 Proteins 0.000 description 4
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 4
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 4
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 3
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000002427 Cyclin B Human genes 0.000 description 2
- 108010068150 Cyclin B Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
- 231100000416 LDH assay Toxicity 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 2
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 2
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- 108010045717 Proto-Oncogene Proteins c-akt Proteins 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- 0 *c(cc1)ccc1-c1cnc(Nc2c(cccc3)c3ccc2)[o]1 Chemical compound *c(cc1)ccc1-c1cnc(Nc2c(cccc3)c3ccc2)[o]1 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BABJIHJYYIFSJO-UHFFFAOYSA-N 2,5-dimethoxyaniline Chemical compound COC1=C(N)C=C(C=C1)OC.COC1=C(N)C=C(C=C1)OC BABJIHJYYIFSJO-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- ZJFWCELATJMDNO-UHFFFAOYSA-N 2-bromo-1-(4-fluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CBr)C=C1 ZJFWCELATJMDNO-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- BNIDBPBBKOFHJO-UHFFFAOYSA-N 4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1.COC1=CC=C(N)C=C1 BNIDBPBBKOFHJO-UHFFFAOYSA-N 0.000 description 1
- CKOFDCHGDOIUIJ-UHFFFAOYSA-N 5-(4-bromophenyl)-n-(5-ethylsulfonyl-2-methoxyphenyl)-1,3-oxazol-2-amine Chemical compound CCS(=O)(=O)C1=CC=C(OC)C(NC=2OC(=CN=2)C=2C=CC(Br)=CC=2)=C1 CKOFDCHGDOIUIJ-UHFFFAOYSA-N 0.000 description 1
- JNXCCEMGDXSTBQ-UHFFFAOYSA-N 5-(4-fluorophenyl)-N-phenyl-1,3-oxazol-2-amine Chemical compound FC1=CC=C(C=C1)C1=CN=C(O1)NC1=CC=CC=C1 JNXCCEMGDXSTBQ-UHFFFAOYSA-N 0.000 description 1
- XDLWNEUYUGKDTC-UHFFFAOYSA-N 5-ethylsulfonyl-2-methoxyaniline Chemical compound CCS(=O)(=O)C1=CC=C(OC)C(N)=C1 XDLWNEUYUGKDTC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- CHLICZRVGGXEOD-UHFFFAOYSA-N Cc(cc1)ccc1OC Chemical compound Cc(cc1)ccc1OC CHLICZRVGGXEOD-UHFFFAOYSA-N 0.000 description 1
- 108010060385 Cyclin B1 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100036723 Discoidin domain-containing receptor 2 Human genes 0.000 description 1
- 101710127786 Discoidin domain-containing receptor 2 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 101150009958 FLT4 gene Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- XQAXGZLFSSPBMK-UHFFFAOYSA-M [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride;trihydrate Chemical compound O.O.O.[Cl-].C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21 XQAXGZLFSSPBMK-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- SQISUZWPWJHTEP-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1.NC1=CC=CC=C1 SQISUZWPWJHTEP-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002700 inhibitory effect on cancer Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- FIGCISKOGMXHSJ-UHFFFAOYSA-N sodium diazide Chemical compound [N-]=[N+]=[N-].[Na]N=[N+]=[N-] FIGCISKOGMXHSJ-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating cancer, a composition for promoting an anticancer therapy effect, or a health functional food for cancer prevention or improvement, which comprises a phenyloxazole derivative represented by Chemical Formula 1 as an active ingredient, , Breast cancer, colorectal cancer, and acute leukemia inhibits the phosphorylation of FLT3 and its substrate protein STAT5, and not only increases cell apoptosis-induced apoptosis, When combined with irradiation, cell proliferation inhibition or cell death due to apoptosis is increased.
Description
The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising a phenyloxazole-based derivative, a composition for enhancing an anti-cancer effect, or a health functional food for cancer prevention or improvement.
Receptor tyrosine kinases (RTKs) are transmembrane proteins that penetrate cell membranes and are one of the most important receptor groups responsible for cell signaling systems that regulate cell proliferation, cell migration, cell cycle and cell differentiation Human RTKs are classified into about 20. Platelet Derived Growth Factor Receptor (PDGFR) can be activated by ligand platelet-derived growth factor (PDGF), mitogen-activated protein kinases (MAPK), phosphatidyl Inositol 3-kinase (PI3K) and STAT3 (signal transducer and activator of transcription 3) can activate the downstream signaling pathway. Activation of PDGFR, including mutations, is observed in GISTs, Glioblastoma multiforme, and chronic myeloid leukemia. An internal tandem duplication (IDT) mutation in the juxtamembrane domain of FLT3 (FMS-like tyrosine kinase 3) gene in approximately 30% of patients with acute myeloid leukemia (AML) About 3% of patients with acute lymphoblastic leukemia (ALL) have mutations, and patients with these mutations are known to have poor prognosis. Thus, FLT3 inhibition may be helpful in the treatment of acute myelogenous leukemia and acute lymphoblastic leukemia. c-Kit can be activated by ligand stem cell factor (SCF), and point mutants such as D816V or V560G are constantly activated without ligand to resist cell proliferation, cell survival and apoptosis Lt; / RTI > In particular, c-Kit activates mastocytosis and induces mastocytosis to increase expression in various organs (skin, liver, gastrointestinal tract, genitalia, etc.) gastrointestinal stromal tumor (GIST), small cell lung cancer, testicular cancer, and polymorphic glioblastoma. Patients with about 70-80% GISTs have a gain-of-function mutation in c-Kit. In addition, we have reported the possibility of rapid growth and metastasis of non-small cell lung cancer due to the activation of c-Kit of non-small cell lung cancer by increasing SCF by nicotine.
Cyclin-depenedent kinase (CDK) is a serine / threonine protein kinase that is crucial to the cell cycle. These complexes consist of two catalytic small molecules, cyclin-dependent kinase (CDK) and regulatory small molecule, cyclin. Each CDK is complexed with a specific cyclin to activate it. The progression of each cell cycle can be controlled by specific CDK / cyclin complexes. CDK1 / cyclin B1, CDK2 / cycle E, and CDK2 / cyclin A are important factors in cell cycle progression.
A number of RTK inhibitors have been tried in clinical trials and have shown initial clinical response, but they are transient and have a problem that resistance may develop rapidly. The RTK inhibitor may cause a D816V mutation in the KIT, a D842V mutation in the PDGFR, and a D835V mutation in the FLT3, interfering with the binding of the RTK inhibitor to the target by various mutations.
Therefore, RTK activation and rapid cell cycle progression are involved in the regulation of abnormal cells in various cancer species. Therefore, the development of inhibitors targeting RTK activity and CDK1 / cyclin B and CDK2 / cyclin A and CDK5 / p35 complex kinase activity Is required.
Accordingly, the present invention provides a pharmaceutical composition for preventing or treating cancer that inhibits a specific kinase.
The present invention also provides a composition for enhancing the effect of an anticancer therapy inhibiting a specific kinase.
The present invention also provides a health functional food for cancer prevention or improvement which inhibits a specific kinase.
In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising a phenyloxazole derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
[Chemical Formula 1]
R 1 is halogen.
delete
delete
delete
According to another aspect of the present invention, there is provided a composition for enhancing an anticancer therapeutic effect, comprising the phenyloxazole derivative represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
According to another aspect of the present invention, there is provided a health functional food for preventing or ameliorating cancer comprising the phenyloxazole-based derivative represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
According to the present invention, there is provided a pharmaceutical composition comprising 5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazole-2- Amine treatment inhibits the phosphorylation of FLT3 and its substrate protein, STAT5, leading to an increase in apoptosis-induced apoptosis, as well as inhibition of cell proliferation or apoptosis in combination with known anticancer agents or radiation irradiation The present invention can be effectively utilized as a pharmaceutical composition for preventing or treating cancer, a composition for enhancing the effect of chemotherapy or a health functional food for cancer prevention or improvement. .
Figure 1 shows that MV4-11 leukemia cells were treated with the derivative 1 [5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol-2-amine] And the phosphorylation of FLT3 and the phosphorylation of STAT5 (signal transducer and activator of transcription 5), a substrate protein of FLT3,
FIG. 2 shows the results of apoptosis-induced apoptosis when the
FIG. 3 shows the results of confirming the production of lactate dehydrogenase (LDH) when H1299, a human lung cancer cell line, was treated with
FIG. 4 shows the result of confirming inhibition of cell proliferation when H1299 was used in combination with the
FIG. 4 shows the results of confirming that cell death was increased when H1299 was used in combination with
Hereinafter, the present invention will be described in detail.
The inventors of the present invention found that Abl, AMP-activated protein kinase alpha 1 (AMP-activated protein kinase alpha 1), ARK5 (AMPK-related protein kinase 5), Aurora-A, cyclin-dependent kinase (CDK1) / cyclin B, CDK2 / cyclin A, CDK5 / p35, (Casein Kinase? 1, CK1? 1), cKit, cKit (D816H), cKit (V560G), cSRC, Discoidin
According to one embodiment of the present invention, a process for producing 5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol- - (naphthalen-1-yl) oxazol-2-amine] was treated with leukemia cells, the degree of phosphorylation of FLT3 protein and the level of STAT5 phosphorylation of FLT3 kinase were inhibited in a concentration-dependent manner.
According to another embodiment of the present invention, there is provided a method for producing 5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol- Apoptosis induced apoptosis occurred when treated with cancer cells.
Accordingly, the present invention provides a pharmaceutical composition for preventing or treating cancer comprising, as an active ingredient, a phenyloxazole derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof.
[Chemical Formula 1]
R < 1 > may be halogen.
delete
delete
delete
The phenyloxazole-based derivative represented by the above-mentioned formula (1) can be produced by reacting 5- (4-bromophenyl) -N- (naphthalen- 1 -yl) oxazol- 1-yl) oxazol-2-amine] or 5- (4-fluorophenyl) -N- (naphthalen- 1 -yl) oxazol- -1-yl) oxazol-2-amine], and more preferably 5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol-2-amine.
Said cancer is selected from the group consisting of lung cancer, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, breast cancer, gastric cancer, liver cancer, colon cancer, skin cancer, head or neck cancer, uterine cancer, ovarian cancer, Cancer, bladder cancer, esophageal cancer, thyroid cancer, bladder cancer, renal cancer, blood cancer, and rectal cancer.
The pharmaceutical compositions according to the present invention may further comprise suitable carriers, excipients or diluents conventionally used in the production of pharmaceutical compositions.
Examples of the carrier, excipient or diluent which can be used in the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil.
The pharmaceutical composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method .
In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose sucrose), lactose, gelatin, and the like.
In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included .
Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
The amount of the phenyloxazole-based derivative which is an active ingredient of the pharmaceutical composition according to the present invention may vary depending on the age, sex, body weight and disease of the patient, but it is preferably 0.001 to 100 mg / kg, more preferably 0.01 to 10 mg / It can be administered once to several times a day.
The dose of the phenyloxazole-based derivative according to the present invention may be increased or decreased depending on the route of administration, degree of disease, sex, weight, age, and the like. Thus, the dosage amounts are not intended to limit the scope of the invention in any manner.
The pharmaceutical composition may be administered to mammals such as rats, mice, livestock, humans, and the like in a variety of routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intratracheal, intrauterine or intracerebroventricular injections.
In another embodiment of the present invention, an anticancer agent or radiation known as 5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol- The effect of the combination therapy on cell proliferation and apoptosis was confirmed.
Accordingly, the present invention provides a composition for enhancing an anticancer therapeutic effect comprising a phenyloxazole derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
[Chemical Formula 1]
R < 1 > may be halogen.
delete
delete
delete
The phenyloxazole-based derivative represented by the above-mentioned formula (1) can be produced by reacting 5- (4-bromophenyl) -N- (naphthalen- 1 -yl) oxazol- 1-yl) oxazol-2-amine] or 5- (4-fluorophenyl) -N- (naphthalen- 1 -yl) oxazol- -1-yl) oxazol-2-amine], and more preferably 5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol-2-amine.
The chemotherapy is chemotherapy or radiotherapy.
The anticancer agent may be selected from the group consisting of 5-fluorouracil, 5-FU, Paclitaxel, Doxorubicin, Daunorubicin, Vinblastine, Vincristine, Actinomycin D, Teniposide, Etoposide, cyclophosphamide, epirubicin, adriamycin, daunomycin, and mitomycin- C (mitomycin-C), but is not limited thereto.
The composition may comprise 1 to 99% by weight of an anti-cancer agent and 1 to 99% by weight of a phenyloxazole-based derivative.
The chemotherapy may be used for the treatment of lung cancer, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, breast cancer, gastric cancer, liver cancer, colon cancer, skin cancer, head or neck cancer, uterine cancer, ovarian cancer, Prostate cancer, bladder cancer, esophageal cancer, thyroid cancer, bladder cancer, renal cancer, blood cancer and rectal cancer, but the cancer is not limited thereto.
In addition, the present invention provides a health functional food for preventing or ameliorating cancer, comprising a phenyloxazole derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
[Chemical Formula 1]
R < 1 > may be halogen.
delete
delete
delete
The phenyloxazole-based derivative represented by the above-mentioned formula (1) can be produced by reacting 5- (4-bromophenyl) -N- (naphthalen- 1 -yl) oxazol- 1-yl) oxazol-2-amine] or 5- (4-fluorophenyl) -N- (naphthalen- 1 -yl) oxazol- -1-yl) oxazol-2-amine], and more preferably 5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol-2-amine.
Said cancer is selected from the group consisting of lung cancer, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, breast cancer, gastric cancer, liver cancer, colon cancer, skin cancer, head or neck cancer, uterine cancer, ovarian cancer, Cancer, bladder cancer, esophageal cancer, thyroid cancer, bladder cancer, renal cancer, blood cancer, and rectal cancer.
The health functional food according to the present invention may be provided in the form of powder, granules, tablets, capsules, syrups or beverages. The health functional food may contain other food or food additives other than the phenyloxazole derivatives according to the present invention, And can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its use purpose, for example, prevention, health or therapeutic treatment.
The effective dose of the phenyloxazole-based derivative contained in the health functional food may be used in accordance with the effective dose of the pharmaceutical composition. However, in the case of long-term intake for health and hygiene purposes or for health control purposes, And the active ingredient can be used in an amount of more than the above range because there is no problem in terms of safety.
There is no particular limitation on the kind of the above health functional food and examples thereof include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, , Drinks, alcoholic beverages and vitamin complexes.
The phenyloxazole derivative of the present invention can be used in the form of a pharmaceutically acceptable salt, and the acid addition salt formed by a pharmaceutically acceptable free acid is useful as the salt. As the free acid, an inorganic acid and an organic acid can be used. As the inorganic acid, hydrochloric acid, bromic acid, sulfuric acid, sulfurous acid, phosphoric acid and the like can be used. As the organic acid, citric acid, acetic acid, maleic acid, fumaric acid, , Acetic acid, glycolic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid, citric acid and arpartic acid. Preferably, hydrochloric acid is used as the inorganic acid, and methanesulfonic acid is used as the organic acid.
In addition, the phenyloxazole derivatives of the present invention include not only pharmaceutically acceptable salts, but also all salts, hydrates and solvates which can be prepared by conventional methods.
The addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving the compound of
The present invention also relates to a phenyloxazole derivative represented by the following formula (2) or a pharmaceutically acceptable salt thereof, wherein the phenyloxazole derivative or a pharmaceutically acceptable salt thereof is in the form of a living body The present invention provides a reagent composition for inhibiting FLT3, which inhibits FLT3 (FMS-like tyrosine kinase 3) in vitro.
(2)
R < 1 > is halogen,
R 2 is naphthyl or ego,
The R 3 to R 5 may be the same or different from each other and may be any one selected from the group consisting of H, -OCH 3, and -SO 2 Et.
The phenyloxazole-based derivative represented by the above-mentioned general formula (2) can be obtained by reacting 5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol- 1-yl) oxazol-2-amine, 5- (4-bromophenyl) -N- (2,5-dimethoxyphenyl) oxazol- 2,5-dimethoxyphenyl) oxazol-2-amine, 5- (4-bromophenyl) -N- (4-methoxyphenyl) oxazole- 4-methoxyphenyl) oxazol-2-amine], 5- (4-bromophenyl) -N-phenyloxazol- 5- (4-bromophenyl) -N- (5- (ethylsulfonyl) -2-methoxyphenyl) -methoxyphenyl) oxazol-2-amine, 5- (4-fluorophenyl) -N- (naphthalen-1-yl) oxazol- -yl) oxazol-2-amine, 5- (4-fluorophenyl) -N-phenyloxazol- 4- (4-fluorophenyl) -N- (4-methoxyphenyl) oxazol-2- amine, N- (2,5-dimethoxyphenyl) -5- (4-fluorophenyl) oxazol-2- N- (5- (ethylsulfonyl) -2-methoxyphenyl) -5- (4-fluorophenyl) oxazole- ) -5- (4-fluorophenyl) oxazol-2-amine].
BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are intended to illustrate the contents of the present invention, but the scope of the present invention is not limited to the following examples. Embodiments of the present invention are provided to more fully describe the present invention to those skilled in the art.
< Reference example 1>
The melting point of the synthesized compound was determined using a Kruess M5000 Melting Point apparatus and the value was not corrected. Proton NMR spectra were recorded on an Avance-300 (Bruker) at 300 MHz. Chemical shifts were recorded in ppm and Me4Si was used as a reference standard.
The mass spectra were recorded on a JEOL, JMS-600W VG Trio-2 GC-MS.
The reaction products were purified using clean column chromatography on silica gel 60 (230-400 mesh, Merck),
< Example 1> Phenyloxazol series Derivative synthesis
The phenyloxazole derivative according to the present invention was synthesized by the reaction shown in
[Reaction Scheme 1]
One. Azide ( Azide ) formation
Bromo-4'-fluoroacetophenone was added to a solution of 4'-bromophenacyl bromide (1.0 eq) in 0.2M acetone or azide Sodium azide (3.0 eq) was added. After stirring and reaction at room temperature for 16 hours, the mixture was filtered and concentrated in vacuo to afford the azide compound (1a-b) (93% yield).
2. Isothiocyanate ( Isothiocyanate ) formation
Dichloromethane (dichloromethane, DCM) in aniline (Aniline) within the amine solution, p - anisidine (p -Anisidine), 2,5- dimethoxy aniline (2,5-Dimethoxyaniline), 1- naphthylamine (1 Thiophosgene (1.2 eq) was treated with 3-amino-4-methoxyphenyl ethyl sulfone (1.0 eq each) and stirred for 4 hours. After the reaction was complete, the mixture was diluted with K 2 CO 3 saturated solution and extracted with DCM at each time.
The combined organic layers were dried under anhydrous MgSO 4 , filtered and concentrated in vacuo to afford the isothiocyanate compound (2a-l).
2. Isoxazole ( Isooxazole ) formation
To a solution of the azide compound (1a-b) (1.0 eq) prepared above and stirring the isothiocyanate compound (2a-1) (1.0 eq) in dioxane (0.2M) was added triphenylphosphine (triphenylphosphine, PPh 3 ) (1.0 eq).
The mixture was stirred for 4 hours while heating to 90 < 0 > C. After the reaction was completed, the reaction mixture was cooled to room temperature, and the solvent was removed by applying pressure. The residue was purified by column chromatography on a silica gel column using ethyl acetate (EtOAc) / hexane (1:10) Purification by chromatography yielded the eluant (3a-j, 32% yield).
R 1 and R 2 of the phenyloxazole derivative represented by the following formula (1) are shown in Table 1 below.
delete
delete
delete
delete
(2)
* DMSO: dimethyl sulfoxide
The results of nuclear magnetic resonance (NMR) of each derivative are as follows.
derivative 1: 5 -(4- Bromophenyl ) -N- (naphthalen-1-yl) Oxazole -2- Amine [5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol-2-
Yellow solid, mp = 183-185 ℃, 1 H NMR (300 MHz, DMSO-d 6) δ 10.19 (s, 1H), 8.30-8.34 (m, 1H), 8.10-8.12 (d, J = 7.32 Hz, 1H), 7.92-7.95 (m, 1H), 7.64-7.67 (m, 3H), 7.48-7.56 (m, 6H); MS (FAB) m / z 365 (M < + & gt ; ).
derivative 2: 5 -(4- Bromophenyl ) -N- (2,5- Dimethoxyphenyl ) Oxazole -2- Amine [5- (4-bromophenyl) -N- (2,5-dimethoxyphenyl) oxazol-2-amine]
Yellow solid, mp = 133-135 ℃, 1 H NMR (300 MHz, DMSO-d 6) δ 10.37 (s, 1H), 7.62-7.65 (m, 4H), 7.52-7.54 (m, 3H), 7.29- 7.34 (m, 2 H), 6.94-6.98 (t, J = 8.99 Hz, 1H); MS (FAB) m / z 316 (MH < + & gt ; ).
derivative 3: 5 -(4- Bromophenyl ) -N- (4- Methoxyphenyl ) Oxazole -2- Amine [5- (4-bromophenyl) -N- (4-methoxyphenyl) oxazol-2-amine]
White solid, mp = 213-215 ℃, 1 H NMR (300 MHz, DMSO-d 6) δ 10.19 (s, 1H), 7.88-7.95 (m, 2H), 7.72-7.76 (d, J = 2.20 Hz, 2H), 7.64-7.67 (dd, J = 5.41, 8.71 Hz, 1H), 7.47-7.50 (m, 2H), 6.91-6.94 (m, 2H), 3.74 (s, 3H); MS (FAB) m / z 346 (MH < + & gt ; ).
derivative 4: 5 -(4- Bromophenyl ) -N- Phenyloxazole -2- Amine [5- (4- bromophenyl ) -N-phenyloxazol-2-amine < / RTI >
White solid, mp = 214-216 ℃, 1 H NMR (300 MHz, DMSO-d 6) δ 9.30 (br s, 1H), 7.86 (q, J = 2.20 Hz, 1H), 7.52-7.85 (m, 5H ), 6.93-6.96 (m, IH), 6.51-6.55 (m, IH), 3.80 (s, 3H), 3.71 (s, 3H); MS (FAB) m / z 376 (MH < + & gt ; ).
Derivative 5: 5- (4-bromophenyl) -N- (5- (ethylsulfonyl) -2-methoxyphenyl) oxazol-2-amine [(5- (4-bromophenyl) -N- (5 - (ethylsulfonyl) -2-methoxyphenyl) oxazol-2-amine]
White solid, mp = 188-190 ℃, 1 H NMR (300 MHz, DMSO-d 6) δ 10.24 (s, 1H), 8.76-8.77 (dd, J = 2.20 Hz, 1H), 7.76 (dd, J = J = 7.15 Hz, 2H), 1.11 (t, J < RTI ID = 0.0 > = 7.43 Hz, 3H); MS (FAB) m / z 437 (M < + & gt ; ).
derivative 6: 5 -(4- Fluorophenyl ) -N- (naphthalen-1-yl) Oxazole -2- Amine [5- (4- fluorophenyl ) -N- (naphthalen-1-yl) oxazol-2-amine]
Yellow solid, mp = 165-167 ℃, 1 H NMR (300 MHz, DMSO-d 6) δ 10.14 (s, 1H), 8.29-8.37 (m, 1H), 8.12 (d, J = 7.32 Hz, 1H) , 7.81-7.99 (m, 1H), 7.43-7.71 (m, 7H), 7.33-7.27 (t, J = 8.99 Hz, 2H); MS (FAB) m / z 305 (MH < + & gt ; ).
derivative 7: 5 -(4- Fluorophenyl ) -N- Phenyloxazole -2- Amine [5- (4- fluorophenyl ) -N- henyloxazole -2-amine]
Light yellow solid, mp = 160-162 ℃, 1 H NMR (300 MHz, DMSO-d 6) δ 10.31 (s, 1H), 7.57-7.68 (m, 5H), 7.26-7.35 (m, 4H), 6.89 -7. 03 (m, 1H); MS (FAB) m / z 254 (M < + & gt ; ).
derivative 8: 5 -(4- Fluorophenyl ) -N- (4- Methoxyphenyl ) Oxazole -2- Amine [5- (4-fluorophenyl) -N- (4-methoxyphenyl) oxazol-2-amine
Pale Brown, mp = 198.6-198.8 ℃, 1 H NMR (300 MHz, DMSO-d 6) δ 10.19 (s, 1H), 8.37 (dd, 2H), 7.53-7.55 (t, J = 8.99 Hz, 2H) 7.30-7.35 (d, J = 2.20 Hz, 2H), 7.24-7.27 (m, 2H), 6.91-6.94 (m, 1H), 3.69 (s, 3H); MS (FAB) m / z 346 (MH < + & gt ; ).
Derivative 9: N- (2,5- Dimethoxyphenyl ) -5- (4- Fluorophenyl ) Oxazole -2- Amine [N- (2,5- dimethoxyphenyl ) -5- (4-fluorophenyl) oxazol-2-amine]
Yellow solid, mp = 214-216 ℃,, 1 H NMR (300 MHz, DMSO-d 6) δ 9.33 (br s, 1H), 7.51-7.72 (m, 6H), 6.91-6.94 (m, 1H), 6.51-6.54 (m, 1 H), 3.87 (s, 3 H), 3.74 (s, 3 H); MS (FAB) m / z 315 (MH < + & gt ; ).
2-methoxyphenyl) -5- (4-fluorophenyl) oxazole- 2-amine [N- (5- (ethylsulfonyl) -2- methoxyphenyl) -5- (4-fluorophenyl) oxazol-2-amine]
Yellow solid, mp = 191-193 ℃, 1 H NMR (300 MHz, DMSO-d 6) δ 10.14 (s, 1H), 8.78 (d, J = 2.20 Hz, 1H), 7.65 (dd, J = 5.41, (M, 3H), 3.98 (s, 3H), 3.20 (q, J = 7.15 Hz, 2H), 1.11 (t, J = 7.43 Hz, 3H); MS (FAB) m / z 377 (MH < + & gt ; ).
delete
delete
delete
delete
delete
delete
< Example 2> Confirmation of inhibition of kinase activity
1. Identification of Inhibitory Effect of
It was confirmed whether the derivative 1 [5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol-2-amine] among the phenyloxazole derivatives synthesized in Example 1 suppressed the kinase activity of RTK Respectively.
Various kinase activity inhibitory effects of the derivative 1 at a concentration of 10 μM were measured using the kinase profiling service of Eurofins. The results are shown in Table 2 below.
As a result, as shown in Table 2, the derivative 1 showed 23 kinds of inhibition of kinase activity, and showed an excellent inhibitory effect especially against cKit (V560G), FLT3, ARK5, Flt4 or cKit kinase.
In addition, the half-maximal inhibitory concentration (IC50) of the derivative 1 was determined for the kinase exhibiting the above-mentioned significant inhibitory effect, and it is shown in Table 3 below.
As a result, as shown in Table 3, the derivative 1 showed excellent inhibitory effect even at a low concentration of kinase except ARK4 and FLT4.
2. Confirmation of inhibitory effect of phenyloxazole derivatives (
Based on the results of the inhibitory effect on the kinase activity of the derivative 1 identified in Example 1 above, the inhibitory effects of
As a result, as shown in Table 4, both
< Example 3> Various human body Cancer cell About Phenyloxazole Identification of the effect of derivatives
The inhibitory effect of the
1. Derivative 1 FLT3 or STAT5 Inhibit phosphorylation effect Confirm
MV4-11 leukemia cells cultured in the above were treated with the derivative 1 synthesized in Example 1 and confirmed by FLAP3 and STAT5 phosphorylation inhibition using Western blot. After treating the derivative 1 at a concentration of 0.1, 1, 2, 5 or 10 μM for 1 hour, cells were obtained and a cell lysate was obtained by a method commonly used in the art. The cell lysate was separated by performing electrophoresis using 9% gradient SDS-PAGE, and transferred to a nitrocellulose membrane (BioRad, Hercules, CA, USA). The membranes were blocked with 5% skim milk and then incubated with primary anti-phospho-FLT3 (Cell signaling, USA), anti-phospho-STAT5 antibody (Santa Cruz Biotechnology (GAPDH, Anti-GAPDH, Santa Cruz Biotechnology) was reacted for 1 hour with a control group (Glyceraldehyde-3-phosphate dehydrogenase, GAPDH, Then, horseradish peroxidase-conjugated anti-mouse IgG antibody (Santa Cruz Biotechnology) was incubated and visualized using an ECL system (GE, USA).
As a result, as shown in Fig. 1, it was confirmed that treatment of
2. Cancer cell Inhibitory effect on survival Confirm
Various cell lines cultured in the above were dispensed into 96-well plates in the number of 3 × 10 3 , and cultured for 24 hours. Then, 10
As shown in Table 5, the derivative 1 [5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol- 2 -amine] according to the present invention was found to be useful in lung cancer, breast cancer, The cell survival rate of CCD18-co and BEAS2B normal cells was inhibited by only about 30% at the same concentration, indicating that they had a selective inhibitory effect on cancer cell proliferation.
The human breast cancer cell line MDA-MB231, human lung cancer cell line H1299, or human colorectal cancer cell line HCT116 cultured as described above was treated with 10
As a result, apoptosis-induced apoptosis was induced in MDA-MB201 breast cancer, H1299 human lung cancer, and HCT116 human colorectal cancer cell lines by 6.6-fold, 4.9-fold, and 3.6-fold, respectively.
In addition, MV4-11, which is an acute leukemia cell, was treated with the
Cells were seeded in 96-well plates at a number of 3 × 10 3 , and cultured for 24 hours. Then, 10 μM of each of the
As a result, as shown in Table 6, it was confirmed that the
3. Lactate dehydrogenase (Lactate Dehydrogenase , LDH ) analysis
In normal cells, the LDH enzyme does not pass through the cell membrane but is released by cell membrane destruction during cell death. Therefore, LDH enzyme can be measured in cell culture to measure apoptosis. First, 10 μM of the derivative 1 was treated for 1, 3, 8, 24, or 48 hours with human lung cancer cell line H1299, and then the cell supernatant was collected and dispensed into a 96-well plate. This was analyzed by spectrophotometric analysis at 450 nm using an LDH assay kit (LDH assay kit, Dojindo, Japan).
As a result, as shown in Fig. 3, LDH enzyme was increased 1.6 times as compared with the control group after 48 hours of treatment with the
< Example 4> Confirmation of anticancer effect by combination treatment with anticancer agent
H1299 lung cancer cells cultured in the same manner as in Example 3 were treated with 5 μM of
As a result, as shown in Fig. 4, when the 5-FU and the derivative 1 were co-administered, the cell proliferation inhibitory effect was increased by 60% or more as compared with the case of 5-FU alone. Accordingly, it has been found that the derivative 1 [5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol-2-amine] as the phenyloxazole derivative according to the present invention can increase the effect It was confirmed that it could be used as an anticancer adjuvant.
< Example 5> Confirmation of anticancer effect by combination treatment with irradiation
H1299 lung cancer cells cultured in the same manner as in Example 3 were dispensed into 6 cm cell culture plates, and the derivative 1 synthesized in Example 1 was treated with 3 or more times of 1 or 5 μM concentration. Then, gamma radiation was irradiated at 2, 4, 6 or 8 Gy and cultured at 5% CO 2 and 37 ° C for 7 days. The cultured cells were recovered, stained with a 1% methylene blue mixed solution in 100% methanol, and the viable cells in which the colonies were formed were counted. The results are shown in Fig. 5A.
As a result, it was confirmed that the surviving fraction was remarkably decreased when 5 μM concentration of the derivative 1 according to the present invention was treated with irradiation.
In addition, cleavage of caspase-3 (caspase-3) involved in apoptosis and PARP (poly-ADP ribose polymerase) involved in DNA repair was confirmed by Western blotting in the same manner as in 1. of Example 3 above. At this time, proteins and cleaved PARP proteins were detected with caspase-3 antibody (Cell signaling technology, Inc. USA) and PARP-1 antibody (PARP-1, Cell signaling technology, Inc. USA).
As a result, it was confirmed that the expression of PARP and truncated caspase-3 protein cleaved when the derivative 1 according to the present invention at a concentration of 5 μM and 1 Gy of radiation were treated together as shown in FIG. 5B.
5, it can be seen that the derivative 1 [5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol-2- amine], which is a phenyloxazole derivative, It is possible to use it as a radiotherapy adjuvant which can increase the effect.
Hereinafter, formulation examples of the
< Prescription example 1 > Prescription example
One. Sanje Produce
1, 20 mg of the derivative, 100 mg of lactose, and 10 mg of talc were mixed and filled in an airtight container to prepare a powder.
2. Preparation of tablets
1, 20 mg of corn starch, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate were mixed and tableted according to a conventional preparation method.
3. Preparation of capsules
1, 10 mg of corn starch, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate were mixed, and the above components were mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
4. Preparation of injections
1, 10 mg of the derivative, the sterile distilled water suitable amount for injection, and the pH adjuster were mixed, and the contents were adjusted to the above contents in the amount of 2 ml per ampoule according to the usual injection preparation method.
5. Manufacture of Ointment
The mixture of the derivative 1, 10 mg, 250 mg of PEG-4000, 650 mg of PEG-400, 10 mg of white petrolatum, 1.44 mg of methyl p-hydroxybenzoate, 0.18 mg of propyl p- To prepare an ointment agent.
< Prescription example 2> Health functional foods
1. Manufacture of health food
(Vitamin A acetate: 70 ㎍, vitamin E: 1.0 mg, vitamin B 1: 0.13 mg, vitamin B 2: 0.15 mg, vitamin B 6: 0.5 mg, vitamin B 12: 0.2 쨉 g,
2. Manufacture of health drinks
1 mg of citric acid, 100 g of oligosaccharide, 2 g of plum concentrate, 1 g of taurine and purified water to make a total of 900 ml, and the above components were mixed according to a conventional health drink manufacturing method, After stirring for 1 hour at 85 ° C, the solution was filtered and sterilized in a sterilized 2 L container, and then refrigerated.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments. It is to be understood that various modifications and changes may be made without departing from the scope of the appended claims.
Claims (14)
[Chemical Formula 1]
R 1 is halogen.
The phenyloxazole-based derivative represented by the above-mentioned formula (1) can be produced by reacting 5- (4-bromophenyl) -N- (naphthalen- 1 -yl) oxazol- 1-yl) oxazol-2-amine] or 5- (4-fluorophenyl) -N- (naphthalen- 1 -yl) oxazol- -1-yl) oxazol-2-amine]. ≪ / RTI >
Said cancer is selected from the group consisting of lung cancer, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, breast cancer, gastric cancer, liver cancer, colon cancer, skin cancer, head or neck cancer, uterine cancer, ovarian cancer, Wherein the cancer is any one selected from the group consisting of cancer, bladder cancer, esophageal cancer, thyroid cancer, bladder cancer, renal cancer, blood cancer, and rectal cancer.
[Chemical Formula 1]
R 1 is halogen.
The phenyloxazole-based derivative represented by the above-mentioned formula (1) can be produced by reacting 5- (4-bromophenyl) -N- (naphthalen- 1 -yl) oxazol- 1-yl) oxazol-2-amine] or 5- (4-fluorophenyl) -N- (naphthalen- 1 -yl) oxazol- -1-yl) oxazol-2-amine]. ≪ / RTI >
Wherein the anticancer therapy is an anticancer therapy or a radiation therapy.
The anticancer agent is selected from the group consisting of 5-fluorouracil, Paclitaxel, Doxorubicin, Daunorubicin, Vinblastine, Vincristine, Actinomycin D, D), teniposide, etoposide, cyclophosphamide, epirubicin, adriamycin, daunomycin, and mitomycin-C. C). ≪ RTI ID = 0.0 > 21. < / RTI >
Wherein the composition comprises 1 to 99% by weight of an anticancer agent and 1 to 99% by weight of a phenyloxazole-based derivative.
The chemotherapy may be used for the treatment of lung cancer, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, breast cancer, gastric cancer, liver cancer, colon cancer, skin cancer, head or neck cancer, uterine cancer, ovarian cancer, Prostate cancer, bladder cancer, esophageal cancer, thyroid cancer, bladder cancer, kidney cancer, blood cancer, and rectal cancer.
[Chemical Formula 1]
R 1 is halogen.
The phenyloxazole-based derivative represented by the above-mentioned formula (1) can be produced by reacting 5- (4-bromophenyl) -N- (naphthalen- 1 -yl) oxazol- 1-yl) oxazol-2-amine] or 5- (4-fluorophenyl) -N- (naphthalen- 1 -yl) oxazol- -1-yl) oxazol-2-amine]. ≪ / RTI >
Said cancer is selected from the group consisting of lung cancer, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, breast cancer, gastric cancer, liver cancer, colon cancer, skin cancer, head or neck cancer, uterine cancer, ovarian cancer, Cancer, bladder cancer, esophageal cancer, thyroid cancer, bladder cancer, kidney cancer, blood cancer, and rectal cancer.
(2)
R < 1 > is halogen,
R 2 is naphthyl or ego,
R 3 to R 5 are the same or different from each other, and are selected from the group consisting of H, -OCH 3, and -SO 2 Et.
The phenyloxazole-based derivative represented by the above-mentioned general formula (2) can be obtained by reacting 5- (4-bromophenyl) -N- (naphthalen-1-yl) oxazol- 1-yl) oxazol-2-amine, 5- (4-bromophenyl) -N- (2,5-dimethoxyphenyl) oxazol- 2,5-dimethoxyphenyl) oxazol-2-amine, 5- (4-bromophenyl) -N- (4-methoxyphenyl) oxazole- 4-methoxyphenyl) oxazol-2-amine], 5- (4-bromophenyl) -N-phenyloxazol- 5- (4-bromophenyl) -N- (5- (ethylsulfonyl) -2-methoxyphenyl) -methoxyphenyl) oxazol-2-amine, 5- (4-fluorophenyl) -N- (naphthalen-1-yl) oxazol- -yl) oxazol-2-amine, 5- (4-fluorophenyl) -N-phenyloxazol- 4- (4-fluorophenyl) -N- (4-methoxyphenyl) oxazol-2- amine, N- (2,5-dimethoxyphenyl) -5- (4-fluorophenyl) oxazol-2- N- (5- (ethylsulfonyl) -2-methoxyphenyl) -5- (4-fluorophenyl) oxazole- ) -5- (4-fluorophenyl) oxazol-2-amine].
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150184931A KR101713027B1 (en) | 2015-12-23 | 2015-12-23 | Composition for preventing or treating cancer comprising phenyloxazol derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150184931A KR101713027B1 (en) | 2015-12-23 | 2015-12-23 | Composition for preventing or treating cancer comprising phenyloxazol derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101713027B1 true KR101713027B1 (en) | 2017-03-07 |
Family
ID=58411287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150184931A KR101713027B1 (en) | 2015-12-23 | 2015-12-23 | Composition for preventing or treating cancer comprising phenyloxazol derivatives |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101713027B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030031998A (en) | 2000-08-29 | 2003-04-23 | 제넨테크, 인크. | Methods for enhancing the efficacy of cancer therapy |
WO2004032882A2 (en) * | 2002-10-10 | 2004-04-22 | Smithkline Beecham Corporation | Chemical compounds |
-
2015
- 2015-12-23 KR KR1020150184931A patent/KR101713027B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030031998A (en) | 2000-08-29 | 2003-04-23 | 제넨테크, 인크. | Methods for enhancing the efficacy of cancer therapy |
WO2004032882A2 (en) * | 2002-10-10 | 2004-04-22 | Smithkline Beecham Corporation | Chemical compounds |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2487875C2 (en) | IMIDAZO[1,2-b]PYRIDAZINE AND PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITOR | |
JP5974124B2 (en) | Compositions of kinase inhibitors and their use for the treatment of cancer and other diseases associated with kinases | |
CA2917344C (en) | Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds | |
JP6963598B2 (en) | Thienopyrimidine compounds, their production methods, pharmaceutical compositions and their applications | |
JP5938400B2 (en) | Pyrrolyl-substituted dihydroindol-2-one derivatives, preparation methods and uses thereof | |
CN101573345A (en) | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | |
KR101789430B1 (en) | Novel compound having SMO-inhibitory activity and composition for preventing or treating cancer comprising the same as an active ingredient | |
US8815863B2 (en) | Compounds and therapeutic use thereof for protein kinase inhibition | |
KR20180066985A (en) | Thienopyrimidine derivative and use thereof | |
CN104230952B (en) | Compound containing pyrimidine skeleton, and preparation method and use of compound | |
JP2022547294A (en) | 3,5-disubstituted pyrazole compounds as kinase inhibitors and their applications | |
CN104557871B (en) | Arylmorpholine compounds with spiro substituents as well as preparation method and use thereof | |
NO342001B1 (en) | C-kit kinase inhibitor for use in the therapeutic treatment of gastrointestinal stromal tumor or mastocytosis. | |
CN107531683A (en) | USP7 inhibitor compounds and application method | |
CN106083704B (en) | Application of-two aryl methylene-N- cyclopropyl piperidine -4- ketone compounds of 3,5- (E) as Hsp90 inhibitor | |
CN116234797A (en) | Heterocyclic inhibitors of TEAD for the treatment of cancer | |
CN104230912B (en) | Quinoline, Its Preparation Method And Use | |
KR101948555B1 (en) | Pharmaceutical composition for preventing or treating cancer comprising receptor tyrosine kinases inhibitor | |
KR101713027B1 (en) | Composition for preventing or treating cancer comprising phenyloxazol derivatives | |
CN108456214B (en) | Quinazoline compound containing oxazole or imidazole structure and application thereof | |
CN106467540A (en) | Pteridine ketone derivatives are as the application of FLT3 inhibitor | |
US11964981B1 (en) | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors | |
CN114539129B (en) | Allylamine bifunctional compound and application thereof | |
US11858935B1 (en) | Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | |
US11945823B1 (en) | Substituted pyrrolo[2,3-d]pyrimidines as CK2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |